Clinical Report: FDA approves therapy for GSDIa

Overview

The FDA has granted accelerated approval to pariglasgene brecaparvovec-opnr (Genglycos) for reducing daily cornstarch intake in patients aged 8 years and older with glycogen storage disease type Ia.

Background

Glycogen storage disease type Ia is caused by glucose-6-phosphatase deficiency, leading to hypoglycemia and long-term metabolic complications. Current management strategies focus on dietary modifications and cornstarch supplementation to maintain euglycemia.

Data Highlights

Key Findings

• Pariglasgene brecaparvovec-opnr is the first approved therapy for glycogen storage disease type Ia.
• The therapy achieved a statistically significant 31% mean reduction in daily cornstarch intake compared to placebo.
• Patients treated with the therapy had a mean decrease of one daily cornstarch dose from baseline compared to placebo.
• Serious adverse reactions included anaphylaxis, adrenal insufficiency, and elevated lactate levels.
• 29% of patients treated experienced hypertriglyceridemia compared to 8% in the placebo group.
• The therapy is contraindicated during pregnancy.

Clinical Implications

Ongoing monitoring for adverse reactions is essential, given the reported serious side effects.

Conclusion

The accelerated approval of pariglasgene brecaparvovec-opnr offers a new treatment option for managing glycogen storage disease type Ia.

Related Resources & Content

1. FDA, FDA, 2026 -- FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia
2. Endocrine Abstracts, ECEESPE2025 -- Efficacy and safety results from a pivotal phase 3 trial of DTX401
3. MDSpire News — FDA Approves Low-IgA IG Therapy
4. glaucoma physician — FDA Grants SPA for Phase 3 Trial of Dazdotuftide
5. reuters — FDA Approves Expanded Use of Gene Therapy for Duchenne Muscular Dystrophy
6. the medicine maker — This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
7. FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia | FDA
8. Efficacy and safety results from a pivotal phase 3 trial of DTX401, an AAV8-mediated liver-directed gene therapy, in individuals with glycogen storage disease type Ia (GSDIa) | ECEESPE2025 | Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course | Endocrine Abstracts
9. Glycogen Storage Disease Type I